title: Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model.
abstract: Mullerian inhibiting substance (MIS) inhibits breast cancer cell growth in vitro. To extend the use of MIS to treat breast cancer, it is essential to test the responsiveness of mammary tumor growth to MIS in vivo. Mammary tumors arising in the C3(1) T antigen mouse model expressed the MIS type II receptor, and MIS in vitro inhibited the growth of cells derived from tumors. Administration of MIS to mice was associated with a lower number of palpable mammary tumors compared with vehicle-treated mice (P=0.048), and the mean mammary tumor weight in the MIS-treated group was significantly lower compared with the control group (P=0.029). Analysis of proliferating cell nuclear antigen (PCNA) expression and caspase-3 cleavage in tumors revealed that exposure to MIS was associated with decreased proliferation and increased apoptosis, respectively, and was not caused by a decline in T antigen expression. The effect of MIS on tumor growth was also evaluated on xenografted human breast cancer cell line MDA-MB-468, which is estrogen receptor- and retinoblastoma-negative and expresses mutant p53, and thus complements the C3(1)Tag mouse mammary tumors that do not express estrogen receptor and have functional inactivation of retinoblastoma and p53. In agreement with results observed in the transgenic mice, MIS decreased the rate of MDA-MB-468 tumor growth and the gain in mean tumor volume in severe combined immunodeficient mice compared with vehicle-treated controls (P=0.004). These results suggest that MIS can suppress the growth of mammary tumors in vivo.
authors.affiliation: Department of Surgical Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.
authors.forename: V
authors.initials: V
authors.lastname: Gupta
authors.forename: J L
authors.initials: JL
authors.lastname: Carey
authors.forename: H
authors.initials: H
authors.lastname: Kawakubo
authors.forename: A
authors.initials: A
authors.lastname: Muzikansky
authors.forename: J E
authors.initials: JE
authors.lastname: Green
authors.forename: P K
authors.initials: PK
authors.lastname: Donahoe
authors.forename: D T
authors.initials: DT
authors.lastname: MacLaughlin
authors.forename: S
authors.initials: S
authors.lastname: Maheswaran
mesh_terms: D000818:Animals; D054304:Anti-Mullerian Hormone; D000941:Antigens / Q000276:immunology / Q000502:physiology*; D017209:Apoptosis / Q000502:physiology; D002455:Cell Division / Q000502:physiology; D003176:Complement C3 / Q000502:physiology*; D006023:Glycoproteins / Q000502:physiology*; D008325:Mammary Neoplasms, Experimental / Q000276:immunology / Q000473:pathology*; D051379:Mice; D016513:Mice, SCID; D008822:Mice, Transgenic; D013735:Testicular Hormones / Q000502:physiology*
chemical_list: D000941:Antigens; D003176:Complement C3; D006023:Glycoproteins; D013735:Testicular Hormones; D054304:Anti-Mullerian Hormone
references.citation: Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):239-44
references.pmid: 11773638
references.citation: J Immunol. 2001 Jan 15;166(2):1156-68
references.pmid: 11145697
references.citation: Semin Cancer Biol. 2000 Apr;10(2):125-44
references.pmid: 10936063
references.citation: Mol Cell Endocrinol. 2003 Dec 15;211(1-2):43-9
references.pmid: 14656475
references.citation: Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15601-6
references.pmid: 14671316
references.citation: Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3214-9
references.pmid: 11248058
references.citation: Mol Endocrinol. 2001 Jun;15(6):946-59
references.pmid: 11376113
references.citation: Oncogene. 2000 Feb 21;19(8):1020-7
references.pmid: 10713685
references.citation: N Engl J Med. 1992 Feb 13;326(7):466-71
references.pmid: 1732773
references.citation: Clin Cancer Res. 2002 Aug;8(8):2640-6
references.pmid: 12171896
references.citation: J Clin Endocrinol Metab. 1996 Feb;81(2):571-6
references.pmid: 8636269
references.citation: J Biol Chem. 2000 Nov 24;275(47):37101-9
references.pmid: 10958795
references.citation: Nat Genet. 2002 Nov;32(3):408-10
references.pmid: 12368913
references.citation: Cell. 1989 Jul 28;58(2):249-55
references.pmid: 2546678
references.citation: Endocr Rev. 2001 Oct;22(5):657-74
references.pmid: 11588147
references.citation: J Biol Chem. 2000 Sep 8;275(36):27973-8
references.pmid: 10854429
references.citation: EMBO J. 1992 Dec;11(13):5013-20
references.pmid: 1464323
references.citation: Development. 1994 Jan;120(1):189-97
references.pmid: 8119126
references.citation: J Biol Chem. 2000 Sep 15;275(37):28371-9
references.pmid: 10874041
references.citation: Ann Oncol. 1994;5 Suppl 4:31-7
references.pmid: 7914742
references.citation: Endocrinology. 1996 Jan;137(1):160-5
references.pmid: 8536608
references.citation: J Biol Chem. 2001 Jul 20;276(29):26799-806
references.pmid: 11356848
references.citation: Mol Endocrinol. 1994 Aug;8(8):1006-20
references.pmid: 7997230
references.citation: Mol Endocrinol. 2001 Jun;15(6):936-45
references.pmid: 11376112
references.citation: Anticancer Res. 2001 Jan-Feb;21(1A):413-20
references.pmid: 11299771
references.citation: Breast. 2000 Oct;9(5):239-46
references.pmid: 14732173
references.citation: Protein Expr Purif. 1992 Jun;3(3):236-45
references.pmid: 1392620
references.citation: J Biol Chem. 2003 Dec 19;278(51):51703-12
references.pmid: 14532292
references.citation: J Clin Endocrinol Metab. 1990 Jan;70(1):16-22
references.pmid: 2294129